FZD4 and diabetic retinopathy: FZD4/LRP5 agonists also reduce neovascular tufts in mice with oxygen-induced retinopathy (16, 47); therefore, this class of agonists appears to target multiple processes relevant to diabetic retinopathy, including promoting BRB function and reducing pathological neovascularization.